home / stock / phcuf / phcuf quote
Last: | $5.95 |
---|---|
Change Percent: | 0.0% |
Open: | $5.95 |
Close: | $5.95 |
High: | $5.95 |
Low: | $5.95 |
Volume: | 100 |
Last Trade Date Time: | 03/06/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$5.95 | $5.95 | $5.95 | $5.95 | $5.95 | 100 | 03-06-2024 |
$5.95 | $0 | $5.95 | $0 | $0 | 67 | 03-04-2024 |
$5.95 | $5.95 | $5.95 | $5.95 | $5.95 | 100 | 03-01-2024 |
$6.5 | $6.5 | $6.5 | $6.5 | $6.5 | 4,000 | 01-23-2024 |
$6.1 | $6.1 | $6.1 | $6.1 | $6.1 | 4,195 | 12-27-2023 |
$4.71 | $0 | $4.71 | $0 | $0 | 1,400 | 12-20-2023 |
$4.71 | $0 | $4.71 | $0 | $0 | 2,901 | 12-08-2023 |
$4.71 | $0 | $4.71 | $0 | $0 | 28,351 | 11-29-2023 |
$4.71 | $0 | $4.71 | $0 | $0 | 9,000 | 11-28-2023 |
$4.71 | $0 | $4.71 | $0 | $0 | 12,783 | 11-27-2023 |
$4.71 | $0 | $4.71 | $0 | $0 | 13,000 | 11-24-2023 |
$4.71 | $0 | $4.71 | $0 | $0 | 7,000 | 11-22-2023 |
$4.71 | $0 | $4.71 | $0 | $0 | 3,044 | 11-21-2023 |
$4.71 | $0 | $4.71 | $0 | $0 | 38,038 | 11-20-2023 |
$4.71 | $0 | $4.71 | $0 | $0 | 79 | 11-16-2023 |
$4.71 | $0 | $4.71 | $0 | $0 | 9,000 | 11-15-2023 |
$4.71 | $0 | $4.71 | $0 | $0 | 430 | 11-14-2023 |
$4.71 | $4.71 | $4.71 | $4.71 | $4.71 | 2,000 | 11-10-2023 |
$5 | $0 | $5 | $0 | $0 | 174 | 11-08-2023 |
$5 | $0 | $5 | $0 | $0 | 20 | 11-07-2023 |
News, Short Squeeze, Breakout and More Instantly...
Photocure Asa Company Name:
PHCUF Stock Symbol:
OTCMKTS Market:
Photocure Partner Asieris Announces Completion of Patient Enrollment in Cevira Phase III Clinical Trial PR Newswire OSLO, Norway , Aug. 9, 2022 /PRNewswire/ -- On August 9, 2022 , Asieris Pharmaceuticals, a global biopharmaceutical company specializ...
Photocure ASA: Results for the first quarter of 2022 PR Newswire OSLO, Norway , May 11, 2022 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix ® /Cysview ® revenues of NOK 81.4 million in the first quarter of 2022 (Q1 ...
Photocure Partner Asieris announces CDE Approval for Hexvix Clinical Real-World Evidence Study in China PR Newswire OSLO, Norway , March 11, 2022 /PRNewswire/ -- Photocure ASA ( PHO: OSE), The Bladder Cancer Company, announces that its partner Asieris Pharm...